UK launches first European arm of Roche’s PrevenTRON Alzheimer’s prevention trial
Screening of up to 1,600 asymptomatic adults begins in the UK, marking the first European rollout of Roche’s PrevenTRON phase‑III study that will test the drug trontinemab in participants with high p‑tau217 levels.
Screening of the first European participants in Roche’s PrevenTRON phase‑III Alzheimer’s prevention trial is set to begin on Monday, 7 September 2026, the day after the Guardian reported the start on 5 September 2026.1 The rollout, conducted by the Surrey and Borders Partnership NHS Foundation Trust, marks the inaugural European enrolment in a study that shifts the focus of Alzheimer’s research from treatment to early‑stage prevention.
Trial design and participant criteria
The trial aims to recruit roughly 1,600 asymptomatic adults aged 55‑80 years from across the United Kingdom.2 Eligibility requires participants to have no memory problems and to test positive for the blood‑based biomarker p‑tau217, which the study uses to identify individuals at elevated risk of future cognitive decline.3 The screening process will be carried out by the Surrey and Borders Partnership NHS Foundation Trust, which will verify the absence of memory impairment before administering the biomarker test.4
Biomarker and drug under investigation
The p‑tau217 biomarker has been linked in previous research to a 78 % ten‑year risk of cognitive impairment for those with the highest levels.5 By selecting participants with elevated p‑tau217, the PrevenTRON study seeks to test whether early intervention with Roche’s experimental antibody trontinemab can halt the progression to dementia.6 Trontinemab, developed by Swiss pharmaceutical company Roche, is designed to target amyloid‑beta plaques, a hallmark of Alzheimer’s pathology.7
Roche’s role and the broader prevention agenda
Roche, a Swiss pharmaceutical firm, is the sponsor of the PrevenTRON trial and provides the investigational drug trontinemab.8 While the company’s UK presence is noted in the packet, detailed corporate information such as the chief executive or employee count remains unverified and will be confirmed against Roche’s own filings before publication.9 The trial aligns with growing policy interest in biomarker‑driven prevention strategies across Europe, where regulators are increasingly encouraging early‑stage interventions to address the rising prevalence of dementia.
| Metric | Value | Unit / Period |
|---|---|---|
| Planned recruitment total | 1,600 | people (overall trial) |
| Age range of participants | 55‑80 | years (overall trial) |
| Estimated ten‑year risk for highest p‑tau217 levels | 78 | % (based on previous research) |
Source: The Guardian – Alzheimer’s trial to test drug on people without symptoms to see if it can be prevented.10
What remains unknown
The packet does not specify the trial’s expected duration, although a separate note mentions a possible four‑to‑six‑year timeframe; without a corroborating source, this cannot be presented as fact.11 Likewise, details about Roche’s UK leadership, headcount, or exact corporate structure are flagged as needing confirmation from the company’s own filings.12 Finally, the trial’s eventual outcomes – whether trontinemab will demonstrably prevent dementia – will only be known after the multi‑year follow‑up period.
For now, the commencement of screening represents a concrete step toward testing a preventive approach that could reshape Alzheimer’s research and policy across Europe.
